Cytek Biosciences, Inc. filings document the reporting, governance, and security structure of a Nasdaq-listed cell analysis solutions company. Its registered security is common stock traded under the CTKB symbol on the Nasdaq Global Select Market.
The company’s 8-K filings furnish financial-results releases, preliminary revenue updates, and related exhibit disclosures under Item 2.02. Proxy and annual meeting filings cover director elections, advisory executive compensation votes, auditor ratification, stockholder voting results, board-class matters, and other governance subjects. Together, these filings describe Cytek’s public-company reporting framework alongside its business in FSP instruments, reagents, software, services, and cell analysis technologies.
Cytek Biosciences, Inc. (CTKB) director Richard Chin reported an exercise and conversion of 6,107 Restricted Stock Units (RSUs) into 6,107 shares of Common Stock on August 18, 2026. Following this transaction, he directly held 28,499 shares of Common Stock and 44,790 RSUs. Each RSU represents a contingent right to receive one share of common stock, with the RSU award vesting in scheduled tranches between August 18, 2025 and August 18, 2026.
Cytek Biosciences, Inc. (CTKB) reported that director and Chief Technology Officer Yan Ming had several Restricted Stock Unit ("RSU Award") tranches vest on August 18, 2026, each RSU converting into one share of common stock. In total, 33,270 shares of common stock were acquired through exercises or conversions of RSUs. To cover related tax obligations, 8,088 shares of common stock were withheld and surrendered to Cytek at $4.67 per share. The RSU Awards vest over four-year schedules, with specified fractions of the total shares vesting on May 18, August 18, November 18, and March 10 of each year for the different grants.
Cytek Biosciences, Inc. granted Chief Legal Officer and Secretary Ilan Feuchtwang new equity awards. The awards consist of 241,416 Restricted Stock Units, each representing one share of common stock, and an option for 127,118 shares of common stock at an exercise price of $4.66 per share, expiring on August 9, 2036. The RSUs and options vest over four years under specified installment schedules, in each case subject to the executive’s Continuous Service under the company’s 2021 Equity Incentive Plan.
Cytek Biosciences, Inc. received an amended Schedule 13G/A disclosing significant ownership positions by Millennium-affiliated entities and Israel A. Englander. Integrated Core Strategies (US) LLC reports beneficial ownership of 7,162,923 shares of common stock, representing 5.5% of the class, all with shared voting and dispositive power. Millennium Management LLC, Millennium Group Management LLC, and Mr. Englander each report beneficial ownership of 9,338,010 shares, or 7.2% of the class, also solely through shared voting and dispositive power. The filing explains that the securities are held by entities subject to voting control and investment discretion of Millennium Management LLC and related managers, and it includes language that this structure should not, by itself, be construed as an admission of beneficial ownership by these reporting persons.
Cytek Biosciences reported total revenue of $48,140 (in thousands) for the quarter ended June 30, 2026, up from $45,602 (in thousands) a year earlier, with growth in both product and service revenue. Higher operating expenses and weaker other income led to a net loss of $12,158 (in thousands), or $(0.09) per share, compared with a loss of $5,583 (in thousands), or $(0.04) per share.
For the first six months of 2026, revenue reached $92,275 (in thousands) while net loss widened to $31,024 (in thousands). Cash and cash equivalents were $73,846 and marketable securities $188,158 as of June 30, 2026, alongside deferred revenue of $47,264 (in thousands) and a legal settlement liability of $8,721 (in thousands).
Cytek Biosciences reported second quarter 2026 revenue of $48.1 million, a 6% increase from the second quarter of 2025, driven by strong instrument growth in the U.S. and China and continued expansion of service revenue. GAAP gross profit was $28.3 million, up 19% year-over-year, with GAAP gross margin improving to 59%, or 53% excluding a one-time tariff refund. Adjusted gross margin was 61%, or 56% excluding the refund.
Operating expenses rose 15% to $39.7 million, including research and development of $9.7 million, sales and marketing of $13.2 million, and general and administrative expenses of $16.8 million, the latter up 24% due to litigation-related expenses, severance and personnel costs. Loss from operations was $11.4 million, and net loss widened to $12.2 million from $5.6 million a year earlier. Adjusted EBITDA moved to a $1.5 million loss from positive $1.3 million in the prior-year quarter.
Cash, cash equivalents and marketable securities totaled $262.0 million as of June 30, 2026, compared to $262.2 million as of March 31, 2026. For full-year 2026, Cytek now expects revenue between $207 million and $212 million, raising the midpoint of its outlook by $1 million, assuming no change in current foreign currency exchange rates.
Boston Partners, a Delaware entity, reports beneficial ownership of Cytek Biosciences, Inc. common stock on a Schedule 13G. It reports holding 7,635,145 shares of common stock, representing 5.91% of the class as of June 30, 2026. Boston Partners has sole voting power and sole dispositive power over all 7,635,145 shares, with no shared voting or dispositive power.
The shares are held in discretionary accounts for certain clients, and Boston Partners may be deemed a beneficial owner under Rule 13d-3. To its knowledge, no other person has rights to dividends or sale proceeds relating to more than 5% of the outstanding common stock referenced.
Cytek Biosciences, Inc. set out separation arrangements for former Chief Legal Officer and Corporate Secretary Valerie Barnett, whose position ended on June 29, 2026. On July 9, 2026, the parties entered into a Severance Agreement including a one-time lump-sum payment of $365,775.12 and payment of COBRA premiums through the earlier of April 30, 2027, or the date she becomes covered under another employer’s group health plan.
If a Change in Control occurs within three months after the Separation Date, Ms. Barnett instead becomes eligible for change-in-control severance equal to 18 months of base salary plus her 2026 bonus target, with the previously paid severance credited, extended COBRA coverage through January 31, 2028, and full vesting of outstanding equity awards. The company also entered into a Consulting Agreement effective July 10, 2026, under which she will provide transition support at $1,000 per hour, up to 10 hours per week, through August 31, 2026, with continued vesting of existing equity awards during her service.
BlackRock, Inc. amended its Schedule 13G to report beneficial ownership of 9,356,551 shares of Cytek Biosciences, Inc. The filing states 9,356,551 shares were beneficially owned, representing 7.2% of the outstanding common stock as of 06/30/2026. The report shows sole voting power of 9,228,737 shares and sole dispositive power of 9,356,551. The filing is signed by a BlackRock managing director on 07/08/2026 and discloses that various persons may have rights to dividends or sale proceeds.
Cytek Biosciences, Inc. filed an initial Form 3 insider ownership report for Ilan Feuchtwang, who serves as Chief Legal Officer and Secretary. The filing is an administrative disclosure of insider status and does not report any share purchases, sales, or other transactions.